Cairo – Mubasher: DBK Pharmaceutical announced higher profits during the first half of 2016, according to a bourse filing.

Net profit rose 2.8% year-on-year to EGP 20.86 million from EGP 20.28 million.

Earlier, the company delayed its IPO due to the instable status of the Egyptian securities market, which don’t reveal the stock’s due fair value.  

The company operates with EGP 149.19 million, divided into 149.19 million shares at EGP 1 each.